[The action of dihydroergotoxine in acute sickling crisis. Results of a double-blind study carried out in French speaking Africa (author's transl)].
A double-blind multicentre study was undertaken in French-speaking African countries, using parallel series in 34 SC homozygous or double-heterozygous subjects suffering from vasculo-occlusive sickling crisis. In the patients treated with dihydroergotoxine, there was a reduction in the duration of the episodes by 43 hours, i.e. more than one quarter of the total duration. This decrease was statistically significant (p is less than 0.05).
D000208:Acute Disease; D000349:Africa; D000755:Anemia, Sickle Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004088:Dihydroergotoxine / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D013997:Time Factors
D004088:Dihydroergotoxine
Action de la dihydroergotoxine sur la crise drépanocytaire. Résultats d'une étude multicentrique en double-aveugle réalisée en Afrique francophone.